PUBLISHER: Grand View Research | PRODUCT CODE: 2067660
PUBLISHER: Grand View Research | PRODUCT CODE: 2067660
The global bioanalytical testing services market size was estimated at USD 5.3 billion in 2025 and is projected to reach USD 11.2 billion by 2033, growing at a CAGR of 9.9% from 2026 to 2033. The market growth is driven by increasing drug development activities for biologics, biosimilars, & personalized medicines, drug approval processes, the increasing complexity of therapeutics, and the rising need for precise analytical validation and regulatory compliance.
Other factors contributing to the market include the rising number of clinical trials, pharmaceutical and biotechnology companies' growing outsourcing to specialized CROs, and technological advancements. In addition, stringent regulatory standards, expanding R&D investments, particularly in emerging markets, and the growing focus on biomarker analysis and pharmacokinetic studies are expected to drive the market growth.
The bioanalytical testing services industry is driven by technological advancements & growing R&D investments, stricter regulatory controls, increasing awareness of bioanalytical testing, and the expansion of bioanalytical testing facilities.
Moreover, technological innovations are significantly driving market growth, as service providers increasingly implement advanced tools, digital platforms, and automation technologies to enhance operational efficiency, accuracy, and scalability. Companies are investing in advanced analytical techniques, automation, and digital solutions to meet the growing complexity of modern drug development, including biologics, biosimilars, and personalized therapies. For instance, in June 2025, IQVIA launched new custom-built AI agents powered by NVIDIA technology, designed to enhance workflows and accelerate insights in life sciences. These AI-driven tools aim to improve efficiency and data processing in bioanalysis, addressing the challenges of handling large and complex datasets and enabling faster, more precise decision-making. Such initiatives are boosting the adoption of these innovative technologies to optimize bioanalytical testing, reduce turnaround times, and support the increasing R&D demands of pharmaceutical and biotechnology companies.
Furthermore, increasing awareness among stakeholders regarding the critical role of bioanalytical testing in ensuring drug safety, efficacy, and quality has fueled demand for these services. Companies recognize that robust bioanalytical testing not only supports regulatory submissions but also mitigates risks, reduces development timelines, and enhances confidence in therapeutic outcomes. This combination of regulatory pressure and informed demand continues to drive the adoption of outsourced bioanalytical testing solutions globally. Besides, stringent regulatory requirements and heightened awareness of the critical role these services play in drug development are expected to drive the market growth.
Regulatory bodies such as the U.S. FDA and the EMA have implemented rigorous standards to ensure the safety, efficacy, and quality of pharmaceuticals and biologics. These regulations necessitate precise and reliable bioanalytical testing, prompting pharmaceutical companies to increasingly outsource these services to specialized providers. For instance, in 2025, SGS expanded its bioanalytical testing services in North America, including method development, validation, pharmacokinetic and immunogenicity testing, to support compliance with FDA and EMA guidelines for clinical trials. This expansion was explicitly aimed at helping pharmaceutical companies meet regulatory standards while ensuring reliable, high-quality data for submissions. Such factors are driving the market growth over the forecast period.
Global Bioanalytical Testing Services Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global bioanalytical testing services market based on molecule, test, workflow, application, end use, and region.